Effect of Milnacipran / Gabapentin in Fibromyalgia

• Status: Enrolling by invitation
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

Gabapentin and milnacipran (MLN) show strong evidence of reduced pain, increased sleep, and improvement in the quality of life in fibromyalgia (FM) patients.

Most FM trials focus primarily on pain reduction with monotherapy. Polypharmacy is commonly used, but supportive evidence is limited.

The gabapentin-MLN combined therapy may be more effective in female patients with FM than their monotherapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Gabapentin; Levomilnacipran; Milnacipran

Criteria

Inclusion Criteria:

• There are no other criteria rather than age and sex

Exclusion Criteria:

• Patient refusal.

• Pregnancy or breastfeeding.

• Active liver disease

• Renal impairment (creatinine clearance < 60 mL/min).

• Documented autoimmune disease.

• Severe chronic obstructive pulmonary disease.

• Recent arrhythmia

• Myocardial infarction

• Stroke.

• Uncontrolled hypertension.

• Glaucoma.